Sort   by:  
 Page size 
TranscriptomicsMouse embryonic kidneys (E13.5): HDAC inhibitor (HDACi) treated vs. Control
Transcriptional profiling of cultured CD1 mouse embryonic kidneys (E13.5) comparing HDACi-treated kidneys with control drug-treated kidneys. Studies in our lab showed that pharmacological inhibition of HDAC activity in ex-vivo cultured metanephroi results in extensive defects in kidney development,...
ORGANISM(S): Mus musculus 
2010-08-01 | E-GEOD-19581 | biostudies-arrayexpress
TranscriptomicsHDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation
Increasing evidence has demonstrated that epigenetic factors can profoundly influence gene expression and, in turn, influence resistance or susceptibility to disease. Epigenetic drugs, such as histone deacetylase (HDAC) inhibitors, are finding their way into clinical practice, although their exact m...
ORGANISM(S): Homo sapiens 
2015-04-10 | E-GEOD-67733 | biostudies-arrayexpress
TranscriptomicsThe HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice
Transcriptional dysregulation has emerged as a core pathologic feature of Huntington's disease (HD), one of several triplet-repeat disorders characterized by movement deficits and cognitive dysfunction. Although the mechanisms contributing to the gene expression deficits remain unknown, therapeutic ...
ORGANISM(S): Mus musculus 
2010-12-27 | E-GEOD-26317 | biostudies-arrayexpress
GenomicsHDACi and PLK1i synergize in MYC-amplified MB
HDACi and PLK1i synergize in MYC-amplified MB
PRJNA911272 | ENA
TranscriptomicsEpigenetic therapy for Friedreich ataxia.
We set out to investigate whether a histone deacetylase inhibitor (HDACi) would be effective in an in vitro model for the neurodegenerative disease Friedreich ataxia (FRDA) and to evaluate safety and surrogate markers of efficacy in a phase I clinical trial in patients. In the neuronal cell model, H...
ORGANISM(S): Homo sapiens 
2015-01-29 | E-GEOD-65399 | biostudies-arrayexpress
UnknownCombination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
Not available
S-EPMC5884928 | biostudies-literature
GenomicsInhibition of cancer cell self-renewal through an epigenetic HDACi-histone H1.0 axis.
Inhibition of cancer cell self-renewal through an epigenetic HDACi-histone H1.0 axis.
PRJNA488996 | ENA
GenomicsDevelopment of a transcriptomic biomarker to detect histone deacetylase inhibitors (HDACi) in TK6 cells
Development of a transcriptomic biomarker to detect histone deacetylase inhibitors (HDACi) in TK6 cells
PRJNA690817 | ENA
GenomicsTranscriptional changes mediated by the HDACi panobinostat in IDH-wildtype and IDH-mutant gliomas
Transcriptional changes mediated by the HDACi panobinostat in IDH-wildtype and IDH-mutant gliomas
PRJNA1331756 | ENA
UnknownInvestigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Not available
S-EPMC5384641 | biostudies-literature
Sort   by:  
 Page size